High-Dose Aflibercept Shows Superior Fluid Control in 96-Week PULSAR Trial Analysis for Wet AMD
Key Insights
Post-hoc analysis of PULSAR (search) phase 3 trial demonstrates aflibercept 8mg achieves comparable fluid-free retinal outcomes to 2mg dosing across all baseline patient demographics, with fewer overall treatments required.
Matched-dose analysis reveals aflibercept 8mg delivers 14-23% higher rates of fluid-free retinas compared to 2mg dosing, with superior central subfield thickness improvements eight weeks post-injection.
Long-term efficacy data through 96 weeks confirms sustained visual acuity and anatomic improvements in treatment-naive neovascular AMD patients with extended dosing intervals.
The phase 3 PULSAR (search) trial's extended 96-week analysis has revealed compelling evidence supporting the enhanced efficacy of high-dose aflibercept in treating neovascular age-related macular degeneration (search) (nAMD), according to findings presented at the Envision Summit 2025 in San Juan, Puerto Rico.
Dr. Deepak Sambhara, partner and medical director of research at the Eye Clinic of Wisconsin (search), presented a comprehensive post-hoc analysis examining fluid outcomes across various baseline demographics in this pivotal trial. The study evaluated aflibercept 8mg administered at 12- or 16-week intervals against the standard 2mg dose given every eight weeks, following initial monthly loading doses.
Consistent Efficacy Across Patient Subgroups
The analysis examined fluid outcomes at three critical timepoints - weeks 16, 48, and 96 - stratifying results by baseline characteristics including central retinal thickness (CRT), visual acuity, choroidal neovascularization (CNV) lesion subtype, and fluid location. Notably, both 8mg and 2mg aflibercept groups achieved comparable proportions of fluid-free retinas across all baseline demographic categories, with the 8mg cohort requiring fewer total treatments.
Superior Fluid Control with Higher Dosing
A matched-dose analysis, designed to address the challenge of asynchronous dosing schedules, revealed that the 8mg formulation demonstrated superior efficacy. "Patients who received 8mg aflibercept were able to achieve fluid-free retinas at a numerically greater value that ranged from 14-23% eight weeks after each active matched injection," Dr. Sambhara explained. This improvement was further supported by greater reductions in central subfield thickness in the 8mg group.
Extended Dosing Benefits
The trial's design allowed for flexible dosing in the 8mg group, ranging from every 8 to 24 weeks, while maintaining fixed 8-week intervals for the 2mg cohort. This adaptability, combined with sustained efficacy through 96 weeks, suggests potential benefits for reducing treatment burden while maintaining optimal therapeutic outcomes.
Clinical Implications
These findings build upon PULSAR (search)'s earlier success in meeting both its primary non-inferiority endpoint for visual acuity at week 48 and its key secondary endpoint measuring fluid-free retinal status at week 16. The persistence of these benefits through 96 weeks, coupled with reduced treatment frequency, positions high-dose aflibercept as a promising advancement in nAMD management.
The comprehensive analysis provides robust evidence supporting the use of higher-dose aflibercept, potentially offering clinicians greater flexibility in treatment scheduling while maintaining or improving anatomical outcomes for patients with wet AMD (search).